Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDABusiness Wire • 01/19/21
CMS Confirms Continued Separate Payment for Omeros' FDA-Approved OMIDRIA® in Ambulatory Surgery CentersBusiness Wire • 12/03/20
Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMABusiness Wire • 11/18/20
Omeros Corp (OMER) CEO Greg Demopulos on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/10/20
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2020Business Wire • 11/05/20
Omeros Participates in Investor Conference Focused on COVID-19 Therapeutics in DevelopmentBusiness Wire • 10/28/20
Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMABusiness Wire • 10/22/20
Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMABusiness Wire • 10/15/20
Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 PatientsBusiness Wire • 09/03/20